CSIMarket


Merus N v   (MRUS)
Other Ticker:  
 


 

Merus N v

MRUS's Financial Statements and Analysis



Merus N v narrowed third quarter of 2023 net loss per share of $-0.43 compare to net loss per share of $-0.53 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.66 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.43 $  11 Mill
$+0.10     $+4M     +67.65 %



Merus N V 's Revenue rose by 67.65 % in third quarter of 2023 (Sep 30 2023) year on year, to $11 million and advanced by 5.32 % sequentially.


Merus N V is

More on MRUS's Income Statement



Merus N V in the third quarter of 2023 recorded net loss of $-23.012 million, an improvement compare to net loss of $-24.615 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-32.033 million realized in previous quarter.

More on MRUS's Growth

Merus N V Inventories
MRUS's Cash flow In the third quarter of 2023 company's net cash flow was $141 million

More on MRUS's Cash flow Statement


Merus N v does not pay out common stock dividend.

In trailing twelve-month period Merus N v payed $ -2.53 cash per share, on a free-cash flow basis .

Book value grew by 37.09 % sequentially to $7.30 per share.
Tangible Book value grew to $ 7.27 per share from $ 5.29.

Company issued 5.55 million shares or 11.48 % in Sep 30 2023.


More on MRUS's Dividends

 Market Capitalization (Millions) 2,956
 Shares Outstanding (Millions) 54
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 46
 Net Income (TTM) (Millions $) -177
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) -12
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Merus N v does not pay out common stock dividend.

In trailing twelve-month period Merus N v had negative $ -2.53 cash flow per share, on a free-cash flow basis .

Book value grew by 37.09 % sequentially to $7.30 per share.
Tangible Book value grew to $ 7.27 per share from $ 5.29.

Company issued 5.55 million shares or 11.48 % in Sep 30 2023.


More on MRUS's Balance Sheets

 Market Capitalization (Millions) 2,956
 Shares Outstanding (Millions) 54
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 46
 Net Income (TTM) (Millions $) -177
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) -12
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Merus N v Earnings

Merus N V Experiences Impressive Revenue Surge and Substantial Reduction in Losses, Signaling Strong Growth in the Major Pharmaceutical Preparations Industry

Respectable Revenue Rise for Merus N V in Q3 2023: A Promising Outlook for the Major Pharmaceutical Preparations Industry
In its recently released report for the third quarter of 2023, Major Pharmaceutical Preparations company, Merus N V, showcased an impressive revenue increase of 67.649% to $11.03 million. This growth has not only supported the company in significantly cutting its losses, reducing the loss per share from $-0.53 in the corresponding quarter of the previous year to $-0.43, but it has also positioned Merus N V advantageously within the Major Pharmaceutical Preparations industry.
When compared to its industry peers, Merus N V outperformed them all in terms of revenue improvement during...

Merus N.V Reports Increased Losses and Declining Revenue in Q2 2023, Spurring Concerns Over Future Performance



Merus N.V, a prominent pharmaceutical company, recently released its financial results for the fiscal period of April to June 2023. These results indicate a mixed bag of outcomes, with both positive and negative aspects to consider. In this article, we will delve deeper into these figures and assess their potential impact on the company's future prospects.
1. Earnings Per Share (EPS) and Losses:
Merus N.V experienced both progress and setbacks in terms of its EPS. On the positive side, the company managed to improve its EPS from a loss of $-0.86 to $-0.66 per share, compared to the previous reporting period. However, this improvement must be weighed against the fact that, a year ago, the co...

Major Pharmaceutical Preparations Company, Merus N V, Witnesses Widened Losses as First Quarter 2023 Earnings Season Unfolds

As an investor, it is important to exercise caution when considering a stock with a cumulative net loss of $-152 million in the 12 months ending in the first quarter of 2023. Merus N V has recorded a negative return on equity (ROE) of -55.8%, which is lower than 51 other companies in the Major Pharmaceutical Preparations industry. It is important to note that while Merus N V's overall ranking has advanced to 1164 from 3414 in the fourth quarter of 2022, the company is still struggling to turn a profitDuring the first quarter of 2023 earnings season, Merus N V increased its deficit per share to $-0.86 from $-0.43 a year prior and from $...


Date modified: 2023-11-03T16:26:27+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com